GADICKE ANSBERT’s insider transaction report records MPM BioVentures 2014, L.P. selling 86,482 Entrada Therapeutics shares across transactions dated 2026-09-01 through 2026-09-03. The disclosed activity matters to investors because it pairs prices of $7.06 to $7.19 per share with remaining ownership of 4,144,952 shares.
Key Highlights
- MPM BioVentures 2014, L.P. sold Entrada Therapeutics shares at prices ranging from $7.06 to $7.19 per share.
- The Partnership owned 4,144,952 Entrada Therapeutics shares after the transactions.
- The seller is identified as an insider of Entrada Therapeutics, Inc.
GADICKE ANSBERT’s insider transaction report records MPM BioVentures 2014, L.P. selling 86,482 shares of Entrada Therapeutics, Inc (NASDAQ: TRDA). The transactions involved an insider position and left the partnership with a disclosed ownership balance after the sales.
Entrada Shares Sold Across September Transactions
The sales were carried out under SEC transaction code S. Prices for the transactions ranged from $7.06 to $7.19 per share. The activity took place between 1 September 2026 and 3 September 2026. The reported sales covered separate transactions during that period. Each price was stated on a per-share basis, while the 86,482 figure represents the total number of Entrada Therapeutics shares sold.
The transaction information therefore identifies both the shares sold and the post-sale ownership reported for the insider partnership.
FAQs
Q: What did GADICKE ANSBERT report about Entrada Therapeutics shares?
A: GADICKE ANSBERT’s report records MPM BioVentures 2014, L.P. selling 86,482 Entrada Therapeutics shares. The transactions occurred between 1 September 2026 and 3 September 2026.
Q: At what prices were Entrada Therapeutics shares sold?
A: The insider transactions were completed at prices ranging from $7.06 to $7.19 per share. The reported range applies to the Entrada Therapeutics shares sold.
Q: How many Entrada Therapeutics shares did MPM BioVentures retain?
A: It only identifies a disclosed post-sale ownership position for the insider partnership.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.